Alimera Sciences Inc/ US0162592028 /
5/31/2024 10:00:00 PM | Chg. -0.0900 | Volume | Bid10:00:13 PM | Ask10:00:13 PM | High | Low |
---|---|---|---|---|---|---|
3.0500USD | -2.87% | 68,810 Turnover: 152,755.4417 |
2.8500Bid Size: 1,000 | 4.9500Ask Size: 100 | 3.2700 | 3.0300 |
GlobeNewswire
5/7
Alimera Announces Scientific Data Highlighting YUTIQ® to be Presented at Upcoming Association for Re...
GlobeNewswire
4/30
Alimera Sciences to Report First Quarter 2024 Financial Results on May 14, 2024, and Provide Corpora...
GlobeNewswire
3/19
Alimera Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRC...
GlobeNewswire
2/29
Alimera Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024, and...
GlobeNewswire
2/8
The UK National Institute for Health and Care Excellence (NICE) Issues Final Draft Guidance to Provi...
GlobeNewswire
1/2
Alimera Sciences Names Elliot Maltz as Chief Financial Officer and Reports Inducement Grant Under Na...
GlobeNewswire
12/12/2023
Alimera Sciences Appoints Todd Wood as President of U.S. Operations and Reports Inducement Grant Und...
GlobeNewswire
11/1/2023
EyePoint Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Corporat...
GlobeNewswire
10/31/2023
Alimera Announces Scientific Data Highlighting ILUVIEN® To Be Presented at the American Academy of O...
GlobeNewswire
10/16/2023
Alimera Sciences to Report Third Quarter 2023 Financial Results on October 26, 2023, and Provide Cor...
GlobeNewswire
10/11/2023
Alimera Announces Multiple Presentations Highlighting ILUVIEN® and YUTIQ® Data at Retina Society Ann...
GlobeNewswire
9/11/2023
EyePoint Pharmaceuticals Reports Positive Masked Safety Update for Lead Product Candidate EYP-1901 i...
GlobeNewswire
9/5/2023
Alimera Sciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference